A5023902861- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Medical Imaging and Pathology Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Voice and Speech Disorders
- Cancer Treatment and Pharmacology
- Tracheal and airway disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer Genomics and Diagnostics
- MRI in cancer diagnosis
- Gastric Cancer Management and Outcomes
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- RNA modifications and cancer
- Pleural and Pulmonary Diseases
- Vascular Anomalies and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Head and Neck Cancer Studies
- Airway Management and Intubation Techniques
- Legionella and Acanthamoeba research
- Liver Disease and Transplantation
University of Tübingen
2010-2023
Ruhrlandklinik
2015-2023
Essen University Hospital
2023
West Cancer Center
2023
Eli Lilly (United States)
2023
Amgen (United Kingdom)
2023
Boehringer Ingelheim (India)
2023
University Children's Hospital Tübingen
2014-2019
Universitätsklinikum Tübingen
2009-2016
Klinik Schillerhöhe
2004-2015
Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by and in patients disease selected IIIB disease. Here, we compared definitive resectable III after induction. Patients Methods pathologically proven that medical/functional operability received chemotherapy, which consisted three cycles cisplatin 50 mg/m 2 on days 1 8 paclitaxel 175 day...
To compare the performance of magnetic resonance (MR)/positron emission tomography (PET) imaging in staging lung cancer with that PET/computed (CT) as reference standard and to quantification accuracy a new whole-body MR/PET system corresponding PET/CT data sets.Institutional review board approval informed consent were obtained. Ten patients whom bronchial carcinoma was proven or clinically suspected underwent indicated fluorine 18 fluorodeoxyglucose (FDG) and, immediately thereafter, hybrid...
The accurate diagnosis of individual interstitial lung diseases (ILD) is often challenging, but a critical determinant appropriate management. If cannot be made after multidisciplinary team discussion (MDTD), surgical biopsy the current recommended tissue sampling technique according to most recent guidelines. Transbronchial cryobiopsy (TBLC) has been proposed as an alternative biopsy.This prospective, multicentre, international study analysed impact TBLC on diagnostic assessment 128...
PURPOSE We started a phase II trial of induction chemotherapy and concurrent hyperfractionated chemoradiotherapy followed by either surgery or boost in patients with advanced, stage III disease. The purpose is to achieve better survival the group minimum morbidity mortality. PATIENTS AND METHODS Patients treated from 1998 2002 neoadjuvant surgical resection for NSCLC were analyzed. treatment consisted four cycles carboplatin/paclitaxel reduced dose accelerated radiotherapy 1.5 Gy twice daily...
Objective To measure perfusion in different lung cancer subtypes and compare results with histopathological/immunohistochemical results. Methods Seventy-two consecutive untreated patients (40 adenocarcinomas, 20 squamous cell, 12 small cell cancers) were enrolled. A 40-second volume computed tomography of the tumor bulk was obtained. Blood flow (BF), blood (BV), transit constant determined. Tumor necrosis determined on contrast-enhanced tomography. Pathologic specimens assessed for...
Rationale: Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome with fatal outcomes. Evidence suggests that dysregulated immune responses, including autoimmunity, are key pathogenic factors. Objectives: To assess whether IgA autoantibodies target lung-specific proteins and contribute severity. Methods: We collected 147 blood, 9 lung tissue, 36 BAL fluid samples from three tertiary hospitals in Switzerland one Germany. Severe COVID-19 was defined by the need...
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation their impact on treatment outcomes.Using databases two cancer networks centers, we molecularly characterized 124...
Purpose: The aim of the study was to evaluate safety, effectiveness, recurrence rate and 10-year survival after bronchial artery embolization (BAE) in benign malignant etiologies. Methods: retrospective includes 100 BAE procedures 88 patients. Underlying disease classified as (n = 67) 21) Immediate bleeding control procedure safety were evaluated all In 51 (58 %) patients, follow-up data with a median time 1015 days (range, 494 3727 days) acquired assess overall survival, time-to-recurrence...
Abstract Purpose Extensive-stage small cell lung cancer (ES-SCLC) carries a dismal prognosis. The benefit of consolidative thoracic radiotherapy (TR) after first-line chemoimmunotherapy with PD-L1 inhibitors in this setting remains unclear. As TR can improve overall survival (OS) conventional chemotherapy, we retrospectively analyzed OS an inhouse cohort treated either or alone. Methods A total 41 patients (atezolizumab durvalumab) for ES-SCLC at our hospital since 2019 were analyzed. was...
7510 Background: Def ccCRTx or + S are accepted therapies (Tx) for OP+ stage IIIA(N2) NSCLC (Albain 2009). Our multicenter phase-II showed efficacy of CTx in / sel IIIB (CISTAXOL: Eberhardt 2013). Here we compared with ccCRTx-BOx III following IND. With 246/500 planned pts (1/04-8/12) trial closed slow accrual futility. report final analysis (29-Jan-2014). Methods: Pathologically proven pts, adequate organ function functional OP+, received IND (3 cycles CDDP/taxol) and to 45 Gy (1.5Gy bid/cc...
Transbronchial lung forceps biopsy (TBLF) is of limited value for the diagnosis interstitial disease (ILD). However, in cases with predominantly peribronchial pathology, such as sarcoidosis, TBLF considered to be diagnostic most cases. The present study examines whether transbronchial cryobiopsy (TBLC) superior terms yield sarcoidosis. In this post hoc analysis a prospective, randomized, controlled, multicentre study, 359 patients ILD requiring bronchoscopic tissue sampling were included....
Static [18F]FDG-PET/CT is the imaging method of choice for evaluation indeterminate lung lesions and NSCLC staging; however, histological confirmation PET-positive needed in most cases due to its limited specificity. Therefore, we aimed evaluate diagnostic performance additional dynamic whole-body PET.A total 34 consecutive patients with pulmonary were enrolled this prospective trial. All underwent static (60 min p.i.) (0-60 (300 MBq) using multi-bed-multi-timepoint technique (Siemens mCT...
7572 Background: EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib lead to prolonged disease stabilization in some patients with advanced NSCLC. It is so far not clear how treat who progress after response erlotinib. TKI therapy beyond progression added chemotherapy, radiotherapy or best supportive care (BSC) may improve survival compared BSC alone. Methods: We retrospectively analyzed all NSCLC treated at our institutions since 2004 progressed least stable on for six months (n=41)....
The detection of molecular alterations is crucial for the individualized treatment advanced non-small cell lung cancer (NSCLC). Missing targetable may have a major impact on patient’s progression free and overall survival. Although laboratory testing has continued to improve; little known about how biopsy technique affects rate different mutations. In retrospective study epidermal growth factor (EGFR) mutations in tissue extracted by bronchoscopic cryobiopsy (CB was significantly higher...
7057 Background: Single-agent gemcitabine (G) and docetaxel (D) are not cross-resistant effective in chemotherapy-naïve pretreated patients (pts). The study was to evaluate the clinically, relevant hematologic toxicity (CRHT) two treatment settings. Interim analysis including survival has been previously presented (ASCO 2004 abstract no. 7095). Methods: Pts received G/D doses of 1000 mg/m2 /75 mg/m2/q3w either concomitantly arm A: {G days 1,8 + D day 8 for 6 cycles} or sequentially B: {G: 3...